白介素37治疗减轻小鼠常染色体显性多囊肾病
该研究利用遗传小鼠模型探讨抗炎细胞因子IL37b对常染色体显性多囊肾病(ADPKD)的治疗潜力。转基因表达人IL37b可减少早发和成年发病ADPKD模型的集合管囊肿负荷,注射重组人IL37b亦有类似效果。机制上,IL37b通过促进肾脏驻留巨噬细胞的I型干扰素信号通路抑制囊肿起始。
要点
- IL37b转基因表达或重组蛋白注射均可减少ADPKD小鼠囊肿负荷
- IL37b作用不依赖早期囊肿形成时巨噬细胞数量的增加
- IL37b通过肾脏驻留巨噬细胞的I型干扰素信号通路发挥保护作用
核心结论
- IL37b通过促进肾脏驻留巨噬细胞的干扰素信号通路抑制囊肿起始,是ADPKD的潜在疗法。
研究设计与样本
- 研究使用遗传小鼠模型,包括早发和成年发病ADPKD模型,进行转基因表达和重组蛋白注射实验。
主要发现
- 转基因表达人IL37b减少早发和成年发病ADPKD模型的集合管囊肿负荷。
- 注射重组人IL37b减少早发ADPKD小鼠囊肿负荷,早期囊肿形成阶段未伴随巨噬细胞数量增加。
- 转基因IL37b表达未改变晚期疾病中的巨噬细胞数量。
- 全肾RNA-seq显示IL37b上调干扰素信号通路,单细胞RNA-seq表明变化至少部分源于肾脏驻留巨噬细胞。
- 阻断表达IL37b小鼠的I型干扰素信号导致囊肿数量增加。
临床怎么用
- IL37b可能作为ADPKD的潜在治疗蛋白,通过调节肾脏驻留巨噬细胞的I型干扰素信号抑制囊肿起始。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a leading cause of kidney failure and is associated with substantial morbidity and mortality. Interstitial inflammation is attributed to the action of infiltrating macrophages and is a feature thought to aggravate disease progression. Here, we investigated the therapeutic potential of the anti-inflammatory IL37b cytokine as a treatment for ADPKD using genetic mouse models, demonstrating that transgenic expression of human IL37b reduced collecting duct cyst burden in both early and adult-onset ADPKD rodent models. Moreover, injection of recombinant human IL37b could also reduce cyst burden in early onset ADPKD mice, an observation not associated with increased macrophage number at early stages of cyst formation. Interestingly, transgenic IL37b expression also did not alter macrophage numbers in advanced disease. Whole kidney RNA-seq highlighted an IL37b-mediated upregulation of the interferon signaling pathway and single-cell RNA-seq established that these changes originate at least partly from kidney resident macrophages. We further found that blocking type I interferon signaling in mice expressing IL37b resulted in increased cyst number, confirming this as an important pathway by which IL37b exerts its beneficial effects. Thus, our studies show that IL37b promotes interferon signaling in kidney resident macrophages which suppresses cyst initiation, identifying this protein as a potential therapy for ADPKD.
引用
- Zylberberg AK, Cottle DL, Runting J, et al. Modulating inflammation with interleukin 37 treatment ameliorates murine Autosomal Dominant Polycystic Kidney Disease. Kidney Int. 2023. PMID: 38158181. doi:10.1016/j.kint.2023.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。